2016 News Releases

Keyword Search
 
DateTitle  
12/08/16Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Topline results from CIMPASI-1, the second of three Phase 3 trials in psoriasis clinical development program Findings confirm CIMZIA results observed in earlier CIMPASI-2 trial Results from third and final Phase 3 trial expected 1Q17 BRUSSELS, Belgium and MENLO PARK, Calif., Dec. 08, 2016 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced topline results from CIMPASI-1, a Phase 3, multi-center, placebo-controlled clinical trial evaluating the effica... 
 Printer Friendly Version
11/09/16Dermira to Present at Stifel 2016 Healthcare Conference
MENLO PARK, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Stifel 2016 Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 11:00 a.m. ET (8:00 a.m. PT) on Wednesday, November 16, 2016, in... 
 Printer Friendly Version
11/07/16Dermira Reports Third Quarter 2016 Financial Results and Provides Corporate Update
- Topline results for the first of three Phase 3 trials for CIMZIA® reported - DRM04 Phase 3 and DRM01 Phase 2b data presented at dermatology conferences - Acquired option to license rights to early-stage programs from Takeda - Licensed DRM04 for hyperhidrosis to Maruho in Japan MENLO PARK, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to impr... 
 Printer Friendly Version
10/21/16Dermira Presents Data from DRM01 Phase 2b Clinical Program at Annual Meeting for Dermatologists
MENLO PARK, Calif., Oct. 21, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, presented data from its DRM01 Phase 2b clinical trial at the 35th Anniversary Fall Clinical Dermatology Conference in Las Vegas. Positive topline results from the DRM01 Phase 2b dose-ranging clinical trial were previously reporte... 
 Printer Friendly Version
10/13/16Dermira to Present Data from DRM01 and DRM04 Clinical Programs at Fall Clinical Dermatology Conference
MENLO PARK, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from its DRM01 and DRM04 clinical programs will be presented at the 35th Anniversary Fall Clinical Dermatology Conference being held in Las Vegas Oct. 20 – 23, 2016. Updated data regarding dose efficacy ... 
 Printer Friendly Version
10/03/16CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Topline results from the first of three Phase 3 trials in psoriasis clinical development program BRUSSELS, Belgium and MENLO PARK, Calif., Oct. 03, 2016 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced topline results from CIMPASI-2, a Phase 3, multi-center, placebo-controlled clinical trial evaluating the efficacy and safety of CIMZIA® (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis. In the CIMPASI-2 trial, CIMZIA ... 
 Printer Friendly Version
10/01/16Dermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
MENLO PARK, Calif., Oct. 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today presented data, including new disease-related quality of life data, from its DRM04 Phase 3 clinical program in patients with primary axillary hyperhidrosis (excessive underarm sweating) in a late-breaking news session at the 2... 
 Printer Friendly Version
09/28/16Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
MENLO PARK, Calif., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from its DRM04 Phase 3 clinical program in patients with primary axillary hyperhidrosis (excessive underarm sweating) will be presented in a late-breaking news session at the 25th European Academy of Derma... 
 Printer Friendly Version
09/20/16Dermira Licenses DRM04 to Maruho for Hyperhidrosis in Japan
Terms include $25 million upfront license payment to Dermira Maruho to fund all development and commercial costs for DRM04 in Japan MENLO PARK, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced it has entered into an exclusive license agreement with Maruho Co., Ltd., a... 
 Printer Friendly Version
09/12/16Dermira Acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from Takeda
MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it has entered into an exclusive option and license agreement with Takeda Pharmaceutical Company Limited (TSE: 4502). Pursuant to the terms of the agreement, Dermira has acquired an option to license exclusive ... 
 Printer Friendly Version
08/08/16Dermira Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Reported Topline Results for Two Late-Stage Clinical Programs Raised Approximately $136 Million in Net Proceeds from Follow-on Public Offering Updates Guidance for Topline Phase 3 CIMZIA® (certolizumab pegol) Clinical Program Results MENLO PARK, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermat... 
 Printer Friendly Version
06/13/16Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it has closed its previously announced public offering of 5,175,000 shares of its common stock, including 675,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of commo... 
 Printer Friendly Version
06/08/16Dermira Prices $126 Million Public Offering of Common Stock
MENLO PARK, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $28.00 per share. The gross proceeds to Dermira from the offering, before deducting the underwriting... 
 Printer Friendly Version
06/07/16Dermira Announces Proposed Public Offering of Common Stock
MENLO PARK, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it intends to offer shares of its common stock in an underwritten public offering. Dermira also expects to grant to the underwriters a 30-day option to purchase additional shares of its common stock in an amount... 
 Printer Friendly Version
06/01/16Dermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in Patients with Primary Axillary Hyperhidrosis
Management to Host Webcast and Conference Call Today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced topline results from its Phase 3 ATMOS-1 and ATMOS-2 pivotal trials for DRM04, a topical anticholinergic product candidate in devel... 
 Printer Friendly Version
05/11/16Dermira to Present Preclinical Data from DRM01 Acne Program at the Society for Investigative Dermatology 75th Annual Meeting
MENLO PARK, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that preclinical data for the DRM01 acne program will be presented in an oral presentation during the Society for Investigative Dermatology 75th Annual Meeting (SID), May 11-14, in Scottsdale, Arizona. The results of ... 
 Printer Friendly Version
05/10/16Dermira Reports First Quarter 2016 Financial Results and Provides Corporate Update
- Positive Topline Results for DRM01 Phase 2b Acne Trial Reported; Phase 3 Program Planning Underway - Announcement of Topline Results for DRM04 Phase 3 Hyperhidrosis Pivotal Trials Expected in Second Quarter of 2016 MENLO PARK, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today repo... 
 Printer Friendly Version
05/10/16Dermira Announces Positive Topline Phase 2b Clinical Trial Results for DRM01 in Patients with Facial Acne Vulgaris
- Safety and Efficacy Data Confirm Results from Previous Phase 2a Trial - DRM01 Phase 3 Clinical Program Planning Underway - Management to Host Webcast and Conference Call Today at 5:30 a.m. PT / 8:30 a.m. ET MENLO PARK, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced topli... 
 Printer Friendly Version
04/05/16Dermira to Present at 15th Annual Needham Healthcare Conference
MENLO PARK, Calif., April 05, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced participation in the 15th Annual Needham Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 12:50 p.m. ET (9:50 a.m. PT) on Tuesday, April 12, 2016, in Ne... 
 Printer Friendly Version
03/14/16Dermira’s Co-founder and Chief Medical Officer, Eugene A. Bauer, M.D., Receives Presidential Citation from the American Academy of Dermatology
MENLO PARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that Eugene A. Bauer, M.D., co-founder and chief medical officer of Dermira, has received a Presidential Citation from the American Academy of Dermatology (AAD). Dr. Bauer received the award at the Stars of the Acad... 
 Printer Friendly Version
03/03/16Dermira Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
Management to Host Webcast and Conference Call Today at 5:30 a.m. PT / 8:30 a.m. ET MENLO PARK, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today reported financial results for the quarter and year ended December 31, 2015 and provided an update on its clinical development programs and ... 
 Printer Friendly Version
03/01/16Dermira to Report Fourth Quarter and Full Year 2015 Financial Results
Management to Host Webcast and Conference Call on March 3, 2016 at 8:30 a.m. ET MENLO PARK, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will report fourth quarter and full year 2015 financial results before the open of U.S. financial markets on March 3, 2016. De... 
 Printer Friendly Version
03/01/16Dermira to Present at Cowen and Company 36th Annual Health Care Conference
MENLO PARK, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Cowen and Company 36th Annual Health Care Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 8:40 a.m. ET on Tuesday, March 8, 2016, in B... 
 Printer Friendly Version
02/29/16Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis
Topline Results for Phase 3 ATMOS-1 and ATMOS-2 Clinical Trials Expected in 2Q 2016 MENLO PARK, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced the completion of patient enrollment in its Phase 3 ATMOS-1 and ATMOS-2 clinical trials for DRM04 in primary axillary hyperhidrosis... 
 Printer Friendly Version
02/04/16Dermira to Present at the Leerink Partners 5th Annual Global Healthcare Conference
MENLO PARK, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Leerink Partners 5th Annual Global Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 11:35 a.m. ET on Thursday, February 11, 2... 
 Printer Friendly Version
01/08/16Dermira Completes Patient Enrollment for Third CIMZIA® (certolizumab pegol) Phase 3 Clinical Trial in Psoriasis Program and Updates Guidance for Release of Topline Data
Enrollment for All Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Plaque Psoriasis Completed Dermira Plans to Announce Topline Data for Phase 3 Trials by End of First Quarter 2017   MENLO PARK, Calif., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced the complet... 
 Printer Friendly Version
01/07/16Dermira Provides DRM01 and DRM04 Development Program Updates
Enrollment Completed in DRM01 Phase 2b Acne Trial; Topline Data Expected in 2Q16 Topline Data for DRM04 Phase 3 Hyperhidrosis Program Expected Mid-2016 MENLO PARK, Calif., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced an update for its DRM01 and DRM04 development programs. Pa... 
 Printer Friendly Version